Back to search results

Understanding Pediatric Solid Tumors

This study aims to understand more about pediatric solid tumors like neuroblastoma, osteosarcoma, Ewing sarcoma, and soft tissue sarcomas. Researchers will analyze tumor samples to learn about their molecular, cellular, and genetic makeup. This includes looking at gene expression (how genes are turned on or off) and genetic changes. The goal is to find better ways to target these cancers with treatments. This study is open to individuals up to 25 years old who have a suspected or known diagnosis of these specific solid tumors. The study is observational, meaning it focuses on collecting information rather than testing a specific treatment. Success will be measured by analyzing gene expression profiles from tumor samples over five years. The current recruitment status is unclear.

Study design
This is an observational study that plans to enroll 1000 participants. It is not testing a specific intervention.
What's involved
Specimens may be collected at initial biopsy, bone marrow aspiration, tumor removal surgery, and other times as needed.
Compensation
Not stated in the trial record.
Follow-up
Gene expression analysis will be measured at 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01050296

Molecular Analysis Of Solid Tumors

Recruiting
Not specifiedUp to 25Observational
St. Jude Children's Research Hospital
~1,000 participants
Updated 2025-11-12 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Perform analysis of gene expression profiles. [RNA] ribonucleic acid will be isolated from fresh frozen tumor specimens and hybridized to Affymetrix gene expression arrays.
Measured over 5 years

Conditions

Pediatric Solid Tumors

Explore related trials

Adrenal Cortical NeoplasmChildhood Solid NeoplasmEwing SarcomaLiver MalignanciesNeuroblastomaOsteosarcomaRetinoblastomaSoft Tissue Sarcoma

Where it's being run

1 sites across 1 states
Tennessee1

Study leadership

  • Sara M. Federico, MD · PRINCIPAL_INVESTIGATOR · St. Jude Children's Research Hospital

Who to contact

Sara M. Federico, MD
[email protected]
1-866-278-5833
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Must have a suspected or known diagnosis of neuroblastoma, osteosarcoma, Ewing sarcoma family of tumor or soft tissue sarcoma based on the initial diagnostic workup and evidence of gross disease amenable to excision. Specimens may be collected at some or all of the following time points: initial biopsy, bone marrow aspiration procedures, tumor resection, and at time of possible relapse.
Patients with a diagnosis of retinoblastoma based on initial diagnostic workup and who require enucleation may be enrolled if there is no active therapeutic or biologic protocol for retinoblastoma.
The patient or his/her legal guardian, as appropriate, must provide written informed consent within 30 days of the removal of the first collection of tissue/bone marrow/blood sample for this protocol.
The patient is being seen at St. Jude Children's Research Hospital or at a collaborating institution.
Patients must be less than or equal to 25 years old at the time of enrollment.

Exclusion

Patient is known to be Hepatitis B, Hepatitis C and/or HIV positive.

What this trial measures

  • Perform analysis of gene expression profiles. [RNA] ribonucleic acid will be isolated from fresh frozen tumor specimens and hybridized to Affymetrix gene expression arrays.5 years